An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

Summary

Objective: In hyperphosphatemic pediatric participants with chronic kidney disease (CKD) to * Evaluate the safety and tolerability of sevelamer carbonate * Evaluate the efficacy of sevelamer carbonate on the control of serum phosphorus

Timeline

Start

2012-05

Primary completion

2015-06

Completion

2015-06

Outcome

Met primary endpoint

registry FDP-Placebo for Sevelamer Carbonate vs FDP-Sevelamer Carbonate; p = 0.001; Least square (LS) mean difference -0.9 (95% CI -1.44 to -0.37) NCT01574326 ↗

Drugs

Indications